Revive Therapeutics Applies To FDA For Orphan Drug

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
66
Revive Therapeutics Applies To FDA For Orphan Drug Designation of Cannabidiol For Treatment Of Liver Transplantation

TORONTO, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) (FSE:31R) (“Revive” or the “Company”) , a specialty medical cannabis company, today announced that it has submitted an application to the U.S. Food and Drug Administration (“FDA”) seeking orphan drug designation of cannabidiol (“CBD”) for the treatment of hepatic ischemia and reperfusion injury (“IRI”) during liver transplantation.

“This orphan drug designation application builds on our pharmaceutical strategy of creating a unique portfolio of cannabinoid therapies targeting rare inflammatory and liver diseases and disorders, and supports our business development activities in partnering with medical-focused licensed producers of cannabis and pharmaceutical companies,” said Fabio Chianelli, President of Revive.  “We are dedicated to commercializing novel medical cannabis-based products and therapies as part of our overall ambition in becoming a leading global specialty medical cannabis company, and we are excited in the long-term potential of plant-derived cannabinoid prescription medicines for rare diseases and disorders, which we believe has been validated by the FDA approval of the GW Pharmaceuticals plc EPIDIOLEX®.  Revive recently announced that the FDA granted orphan drug designation for cannabidiol in the treatment of autoimmune hepatitis, a rare liver disease, and our orphan drug application in liver transplantation is complementary to our liver disease pharmaceutical strategy.”

Liver ischemia-reperfusion injury is a major complication of liver transplantation and is one of the leading causes for post-surgery hepatic dysfunction leading to an increased risk of postoperative morbidity and mortality.  According to the United Network for Organ Sharing (“UNOS”) there have been 160,722 liver transplants performed between January 1, 1988 and July 30, 2018.  Currently there are 13,773 individuals on the waiting list for a liver transplant.  Quickly restoring blood supply of ischemic liver as soon as possible is crucial for avoiding or reducing injury from ischemia, whereas strategies used to attenuate the damage induced by reperfusion, including ischemic preconditioning, ischemic postconditioning, and machine perfusion.  These strategies are expensive, sometimes hard to perform in clinical surgeries, and difficult in maintaining liver functions in the case of acute injuries.  Revive believes that the immunosuppressant and anti-inflammatory protective effects of CBD  may provide a novel, more beneficial strategy to attenuate the damage induced by ischemia and reperfusion during liver transplantation.

Under the Orphan Drug Act of 1983, the FDA provides incentives for companies developing treatments that are expected to provide significant therapeutic advantage over existing treatments, and that target rare medical conditions affecting fewer than 200,000 U.S. patients per year.  Incentives include seven-year market exclusivity, tax credits on U.S. clinical trials, fast-tracking of regulatory proceedings, and exemption from certain fees, such as waiver of filing fees under the Prescription Drug User Fee Act (PDUFA), and orphan drug grants.

About Liver Disease Liver disease is described as irregular functioning of liver, causing disorders like hepatitis, fatty liver (NASH), and cirrhosis.  There are over 100 described diseases of the liver affecting at least 30 million people alone in the U.S.  A number of factors are driving the liver disease treatment market, which includes rapidly changing lifestyle patterns such as increasing alcohol consumption, unhealthy diets, and increasing prevalence of liver diseases.  Liver diseases can result from injury to the liver caused by hepatitis C virus (HCV), hepatitis B virus (HBV), obesity, chronic excessive alcohol use or autoimmune diseases.  Major drug categories used in the treatment of liver diseases includes anti-rejection drugs, vaccines, immunosuppressant, chemotherapy drugs and antiviral drugs.  According to Allied Market Research titled, “World Liver Disease Treatment Market – Opportunities and Forecast, 2014 - 2022”, the global market for liver disease treatment is projected to reach approximately $19.5 billion by 2022.

About Revive Therapeutics Ltd. Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) (FSE:31R) is a specialty medical cannabis company focused on the research, development and commercialization of novel cannabinoid-based therapies.  Additional information on Revive is available at www.ReviveThera.com .

For more information please contact: Craig Leon Chief Executive Officer Revive Therapeutics Ltd. Tel: (416) 272-5525 Email: craig@revivethera.com Website: www.revivethera.com

Revive Therapeutics Ltd. Cautionary Note Regarding Forward-Looking Statements

Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.

This news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute “forward-looking information” that involves known and unknown risks and uncertainties, which are not comprised of historical facts, and most of which are beyond the control of Revive. Forward-looking statements include estimates and statements that describe Revive’s future plans, objectives or goals, including words to the effect that Revive or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “intends”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”, and similar expressions. Specifically, forward-looking statements in this news release include, without limitation, statements regarding: Revive’s orphan drug designation of cannabidiol in the treatment of hepatic ischemia and reperfusion injury (“IRI”) during liver transplantation; Revive’s orphan drug designation of cannabidiol in the treatment of autoimmune hepatitis; Revive’s cannabis pharmaceutical, research and development, and commercialization strategy; pharmaceutical strategy of creating a unique portfolio of cannabinoid therapies targeting rare inflammatory and liver diseases and disorders; Revive’s drug research and development, and commercialization plans; Revive’s research, development and commercialization plans for plant-based therapies, including cannabinoids; Revive’s cannabinoid delivery technology; Revive’s cannabinoid-based product pipeline; the timing of operations; and estimates of market sizes and conditions. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events, performance, or achievements of Revive to differ materially from those anticipated or implied in such forward-looking statements. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Revive believes that the expectations reflected in these forward-looking statements are reasonable, but there can be no assurance that actual results will meet management's expectations. In formulating the forward-looking statements contained herein, management has assumed: that business and economic conditions affecting Revive will continue substantially in the ordinary course and will be favourable to Revive; that clinical testing results will justify commercialization of the Revive’s drug candidates; that Revive will be able to obtain all requisite regulatory approvals to commercialize its drug candidates; that such approvals will be received on a timely basis; and, that Revive will be able to find suitable partners for development and commercialization of its drug repurposing candidates on favourable terms. Although these assumptions were considered reasonable by management at the time of preparation, they may prove to be incorrect and no assurance can be given that such events will occur in the disclosed time frames or at all.

Factors that may cause actual results to differ materially from those anticipated by these forward-looking statements include: uncertainties associated with obtaining regulatory approval to perform clinical trials and market products; the need to establish additional corporate collaborations, distribution or licensing arrangements; Revive’s ability to raise additional capital if and when necessary; intellectual property disputes; increased competition from pharmaceutical and biotechnology companies; changes in equity markets, inflation, and changes in exchange rates; and other factors as described in detail in Revive's Management's Discussion & Analysis for the period ended June 30, 2017 and Revive's other public filings, all of which may be viewed on SEDAR ( www.sedar.com ). Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. Except as required by law, Revive disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 92

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
NextPlat’s 150-Patient Test Has a Long Road Ahead

Updated Category News Views 114

A strip of pills can look mundane, yet it is where this entire NextPlat pitch either earns its keep or falls apart. PharmcoRx has signed a partner pharmacy agreement with MedSure Systems for a 150-patient Medicare medication-adherence pilot in South Florida. That is a small starting line, no two ways around it. Still, the mechanics are more interesting than another vague...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 156

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
Wenge AI Removes a Small Friction Point for ScienceOra

Updated Category News Views 31

Scientific software rarely loses users because the underlying model is too clever; it loses them because getting through the front door is a nuisance. Wenge AI has addressed that unglamorous problem by adding Google and Apple sign-in options to the international version of ScienceOra, its AI-powered research and decision-support platform. This is not the sort of...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 90

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 162

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading
SAP Execution Can Steady Operations Beyond Spreadsheets

Updated Category News Views 87

Spreadsheets breed little kingdoms, and SAP is often left outside the gate. That is the operational mess Martin Rowan, managing partner at Reveal USA, Inc. in Naperville, is taking aim at in a Nov. 19, 2026 HelloNation feature. His central point is not terribly glamorous, but it is dead right: a company gets less stable when it uses SAP to explain yesterday's results...

Continue Reading
LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 98

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
Huawei's Financial AI Push Targets Scale, Not Demos

Updated Category News Views 23

Banking AI has reached the point where a clever chatbot barely moves the needle. Huawei's message at Singapore FinTech Festival 2026 was aimed squarely at that harder, more expensive problem: turning AI from a scattered pilot project into machinery a financial institution can operate, govern, repeat, and improve without handing over its crown jewels. Ownership Is the...

Continue Reading
CMS Audit Proposal Reopens Medicare Advantage Risk

Updated Category News Views 44

A regulator just tossed a rusted anchor into managed care's earnings model. CMS's proposed Comprehensive Regulations to Uncover Suspicious Healthcare rule, dubbed CRUSH and numbered CMS-6098-P, puts Medicare Advantage risk-adjustment audits back at center stage. The headline nobody can casually wave away: audit findings from sampled enrollees could be extrapolated across...

Continue Reading

Top 5 Most Recently Viewed Articles

Anticipating Autohome Inc.'s Financial Results for 2025

Updated Category News Views 150

Autohome Inc.'s Upcoming Financial Results Announcement Autohome Inc. (NYSE: ATHM) is on the verge of announcing its financial results for the second quarter and six months period ending June 30, 2025. As a leading platform for automobile consumers, Autohome continues to grow and adapt in an evolving market. Key Details on the Earnings Announcement The earnings report...

Continue Reading
NEXGEL Welcomes Industry Expert Kip Crecca to Advisory Team

Updated Category News Views 100

NEXGEL Expands Scientific Expertise with New Appointment NEXGEL, Inc. (NASDAQ: NXGL), renowned for its innovative medical and over-the-counter (OTC) products, has recently announced an exciting development. The company is thrilled to welcome Kip Crecca to its Scientific Advisory Board. This strategic addition showcases NEXGEL's dedication to enhancing its healthcare...

Continue Reading
Exciting Mixed-Use Development Takes Shape in Downtown Area

Updated Category News Views 318

Reimagining Urban Spaces: The Lewter District Development In an exciting development for urban living, RNGD and Emergent Properties are pioneering a remarkable mixed-use community known as the Lewter District. This project is set on a 1.5-acre plot, featuring 14 townhomes, a Class A office building, and an inviting farm-to-table restaurant, bar, and bakery. It's an...

Continue Reading
37th Parallel Expands DFW Footprint with Key Acquisition

Updated Category News Views 97

Picking Up Momentum in Dallas-Fort Worth Real Estate 37th Parallel Properties isn't messing around in the Dallas-Fort Worth market. They've snapped up Woodbridge Villas, a prime multifamily asset with 222 units tucked away in Sachse, Texas—a place with more charm than lawn gnomes in spring. This acquisition helps them expand their already hefty footprint in the South...

Continue Reading
Microchip Technology Announces Revenue Changes and Restructuring

Updated Category News Views 169

Microchip Technology's Updated Revenue Guidance for December Quarter Recently, Microchip Technology Incorporated, a prominent provider of smart embedded control solutions, has updated its revenue outlook for the upcoming quarter. The latest forecasts indicate a decline, with expectations set close to the lower end of their original guidance at $1.025 billion. This...

Continue Reading